Wegovy 7.2 mg Is Approved: What the Highest Dose Says About the Lowest

The FDA approved Wegovy HD, a 7.2 mg weekly dose of semaglutide, on March 19, 2026. In the STEP UP trial it produced 18.7% average weight loss at 72 weeks, against 15.6% on the standard 2.4 mg dose. Tripling the dose added about three percentage points: the semaglutide curve flattens at the top.

That shape is the useful part for anyone thinking about a low dose. The 7.2 mg approval is mostly news for people who have plateaued on 2.4 mg. But it also completes the dose ladder, and a complete ladder shows where each milligram buys the most.

What was approved, and for whom?

Wegovy HD is a single-dose pen that delivers 7.2 mg in 0.75 mL ¹. The label allows it only for adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction ¹. It is not a starting dose; everyone still begins at 0.25 mg and climbs through 0.5, 1 and 1.7 mg to 2.4 mg first ¹.

Novo Nordisk announced the approval on March 19, 2026, and said the pen would reach pharmacies in April ².

How much weight does each semaglutide dose take off?

Four trials give the shape of the curve.

At the top, STEP UP. In 1,407 adults with obesity and no diabetes, 72 weeks of 7.2 mg produced 18.7% average weight loss, versus 15.6% on 2.4 mg and 3.9% on placebo, counting everyone randomized ³. Novo's estimate for people who stayed on treatment was 20.7% versus 17.5% ². The bigger difference shows up at the far end: 31.2% of people on 7.2 mg lost a quarter of their body weight or more, versus 15.3% on 2.4 mg ².

In type 2 diabetes, STEP UP T2D. Weight loss was 13.2% on 7.2 mg against 3.9% on placebo ⁴, and the label reports 10.4% for the 2.4 mg arm of that trial ¹. Diabetes shrinks the numbers at every dose.

In the middle, STEP 1. The trial behind the original approval found 14.9% average loss at 2.4 mg versus 2.4% on placebo over 68 weeks ⁵.

At the bottom, a dose-ranging trial. A phase 2 trial tested daily semaglutide injections from 0.05 to 0.4 mg for 52 weeks. Average weight loss was 6.0% at 0.05 mg, 8.6% at 0.1 mg, 11.6% at 0.2 mg, 11.2% at 0.3 mg and 13.8% at 0.4 mg, against 2.3% on placebo ⁶. Those were daily doses, so they can't be lined up milligram for milligram against weekly ones, but the shape is clear.

Put the ends together and the pattern is lopsided. At the bottom, small increases in dose bought several points of weight loss each. At the top, going from 2.4 to 7.2 mg, three times the drug, bought about three points ³. That is classic dose-response: steep early, flattening late. The longer version of this argument, across semaglutide and tirzepatide, is in GLP-1 dose-response.

Do side effects rise with the dose?

Yes, and one of them is new enough to name.

In STEP UP, gastrointestinal side effects hit 70.8% of people on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo. Dysesthesia, an altered or unpleasant skin sensation, was reported by 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo ³. The label lists 5.4% of people on 7.2 mg stopping for side effects, against 1% on placebo ¹.

The lower rungs show a gradient too. In STEP 2, in people with type 2 diabetes, gastrointestinal side effects were reported by 57.5% on semaglutide 1 mg, 63.5% on 2.4 mg and 34.3% on placebo ⁷. In the daily dose-ranging trial, the most common side effects were dose-related gastrointestinal symptoms, mainly nausea ⁶.

What does 7.2 mg cost compared with starting doses?

On NovoCare, read October 2, 2026, self-pay Wegovy injections cost $349 a month at every strength from 0.25 to 2.4 mg, and $399 a month for Wegovy HD 7.2 mg. New patients pay $199 for each of their first two monthly fills of 0.25 or 0.5 mg through December 31, 2026 ⁸.

So on the brand, the starting doses are not cheaper per month than 2.4 mg once the introductory offer runs out. The $199 offer is the only point where a low dose costs less. Compounded semaglutide usually prices differently; current plans are compared on the cheapest microdose semaglutide board.

What this means for a 0.25 mg microdose

The 7.2 mg result is good news for people who need more than 2.4 mg can give. For a low-dose reader, it says something less comfortable.

If the curve were flat everywhere, a small dose would deliver most of the benefit. STEP UP shows the curve is flat only at the top. The dose-ranging data show it is steep at the bottom, where a microdose sits. Each step down from the starting rungs is expected to cost more weight loss per milligram than each step up from 2.4 mg gains.

And 0.25 mg is not a tested maintenance dose. On the label it is the first four weeks of a titration ¹, and no trial has measured what holding it for a year does. A microdose below 0.25 mg is further off the edge of the data. That doesn't make low-dose use pointless for every goal; some people want appetite control or fewer side effects rather than maximum loss. The trade-offs are laid out in low-dose vs full-dose GLP-1, and the Wegovy-specific version is in microdosing Wegovy. Staying below the label's maintenance doses is off-label and unproven.

What 7.2 mg changes is the ceiling. The floor is exactly as uncertain as it was before.